Divis Labs Q3 Results: Profit rises 17% YoY to Rs 358 crore

Pharma major Divis Laboratories on Saturday reported a consolidated net profit of Rs 358 crore for the quarter ended December 2023, up 17% from Rs 306 crore posted in the same period last year.

Revenue from operations in the reporting period increased 9% year-on-year to Rs 1,855 crore, compared with Rs 1708 crore in the corresponding period of last year.

EBITDA for the third quarter jumped 20% year-on-year to Rs 489 crore, as against Rs 409 crore in the same quarter of last year. Meanwhile, margins improved to 26.4%.


Profit before Tax (PBT) for the quarter came in at Rs 489 crore, as against a PBT of Rs 435 crore during the corresponding quarter of last year.

Material consumption for this quarter came to be about 39% of sales revenue.

For the nine-month period ended December 2023, the company earned a PAT of 1,062 crore, down 29% year-on-year from Rs 1,502 crore in the same period of last year.

The company reported a total income of Rs 5804 crore in the 9MFY24 period.

Forex gain for the current 9-month accounted for Rs 32 crore as against Rs 134 crore during the previous 9-month period.

The company's board has approved the reappointment of Sunaina Singh as an Independent Director for a second term of five years effective from March 28, 2024.

Further, the board has also approved the appointment of Devendra Rao as Additional Director designated as ‘Whole-time Director (Manufacturing), for a term of 5 years from February 10.

Total expenses during the third quarter increased 5% year-on-year to Rs 1,461 crore. The same stood at Rs 1,386 crore a year ago.

On Friday, Divis Labs shares closed 0.8% lower at Rs 3,655 on NSE.